It is also noteworthy that both anti-VEGF agents, in addition to preventing the fall of cell viability and preserving mitochondrial membrane potential, were also able to increase cell proliferation and migration [205] (Figure 5), in contrast with some in vivo studies reporting evidence that anti-VEGF treatment can potentially increase the rate of development of macular atrophy in AMD, though data in the literature on this topic are controversial and not conclusive [208,209,210,211,212,213]. Here, VEGFA is linked to age-related macular degeneration.